From molecular viewpoint, endometrial cancer resembles proliferative rather than secretory endometrium, which suggests that the abnormity of tumor-suppressor genes such as PTEN, KRAS, TP53 and ERBB-2 can accelerate the development of endometrial cancer [6–10]. This evidence concerns the gene TP53 and endometrial cancer.